Post-essential Thrombocythemia Myelofibrosis clinical trials at UCSD
1 research study open to eligible people
Showing trials for
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
open to eligible people ages 18 years and up
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
La Jolla, California and other locations
Our lead scientists for Post-essential Thrombocythemia Myelofibrosis research studies include Catriona Jamieson.
Last updated: